Bernstein initiated coverage on Cronos Group with a new price target
$CRON
Medicinal Chemicals and Botanical Products
Health Care
Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $3.00 | Mkt Perform | Bernstein |
| 7/28/2022 | Hold → Buy | Canaccord Genuity | |
| 5/11/2022 | Neutral → Sector Outperform | CIBC | |
| 3/22/2022 | Underweight → Equal Weight | Barclays | |
| 3/7/2022 | $4.00 → $3.00 | Neutral | Piper Sandler |
| 2/22/2022 | $7.00 → $4.25 | Sell | Canaccord Genuity |
| 2/22/2022 | $7.00 → $4.00 | Neutral | Piper Sandler |
| 1/27/2022 | $5.54 → $3.24 | Underperform → Hold | Jefferies |
SD - Cronos Group Inc. (0001656472) (Filer)
10-Q - Cronos Group Inc. (0001656472) (Filer)
8-K - Cronos Group Inc. (0001656472) (Filer)
Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00
Canaccord Genuity upgraded Cronos Group from Hold to Buy
CIBC upgraded Cronos Group from Neutral to Sector Outperform
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the e
TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and
TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders (the "Meeting") reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.g
TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announced today that it is expanding distribution with its PEACE NATURALS® medical cannabis brand in the Swiss market through its partnership with Dascoli Pharma AG ("Dascoli"), a Swiss-based company specializing in the supply and distribution of medical cannabis and healthcare training. "We are excited to partner with Dascoli to bring high-quality medical cannabis to Swiss patients," said Mike Gorenstein, Chairman, President and CEO, Cronos. "This partnership aligns with our mission to provide borderless cannabis products to European medical markets. Expanding our presence
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the e
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the TD Cowen 9th Annual Future of the Consumer Conference on Wednesday, June 4, 2025, at 3:30 p.m. EST. A live webcast will be available on the Investors section of the Company's website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group Inc.Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to r
4 - Cronos Group Inc. (0001656472) (Issuer)
4 - Cronos Group Inc. (0001656472) (Issuer)
4 - Cronos Group Inc. (0001656472) (Issuer)
TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on t
TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 fourth-quarter and full-year earnings conference call on Thursday, February 27, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch
TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay
SC 13D/A - Cronos Group Inc. (0001656472) (Subject)
SC 13D/A - Cronos Group Inc. (0001656472) (Subject)